eXciteOSA® Daytime Sleep Apnea Therapy Now Covered by Georgia Medicaid
Signifier Medical Technologies Limited (“Signifier”), a global leader in sleep-disordered breathing treatments, announced today that its non-invasive daytime therapy, eXciteOSA®, is now covered under Georgia Medicaid policy 1320. This development enhances access to innovative care for over 1.5 million Georgians enrolled in Medicaid, offering a new solution to combat the economic burdens associated with untreated sleep apnea.
Obstructive sleep apnea (OSA) impacts nearly 54 million Americans, contributing to serious health issues such as heart disease, stroke, and diabetes. Untreated OSA also carries a significant economic burden, costing the U.S. an estimated $94.9 billion annually, according to a 2021 study in the Journal of Clinical Sleep Medicine. In Georgia, this translates into rising healthcare costs, lost productivity, and safety concerns in key sectors like logistics and manufacturing.
“This decision highlights the importance of providing accessible, effective solutions for Georgians living with obstructive sleep apnea,” said Akhil Tripathi, Director and Founder of Signifier. “By adding eXciteOSA® to Medicaid coverage, Georgia is not only prioritizing patient outcomes but also addressing a broader economic challenge by lowering the long-term costs tied to untreated or poorly managed sleep apnea.”
Unlike traditional treatments such as CPAP (continuous positive airway pressure) machines, which are often cumbersome and lead to low adherence rates, eXciteOSA® offers a non-invasive, user-friendly alternative. The therapy, which strengthens airway muscles in just 20 minutes per day, has a high adherence rate of over 80%. For Medicaid recipients, this therapy provides an effective, practical option for improving health outcomes and lowering the systemic costs associated with untreated OSA.
Physicians have observed significant improvements with the daytime therapy. “As someone who has prescribed eXciteOSA®, I’ve seen its positive impact firsthand,” said Dr. Hitendra Patel, a sleep specialist based in Georgia. “Many of my patients, including those who struggled with CPAP machines, report improved sleep quality, higher energy levels, and overall better well-being. With Medicaid coverage, even more people can access this transformative therapy.”
Georgia’s decision to expand Medicaid coverage reflects the state’s commitment to reducing healthcare disparities and improving economic outcomes. By introducing innovative treatments like eXciteOSA®, which enhances adherence and health results, Georgia is setting an example of how targeted policies can offer long-term benefits for both individuals and the economy.
About Signifier Medical Technologies
Signifier is a leader in addressing the root causes of sleep-disordered breathing. The company focuses on developing and commercializing non-invasive solutions that help people breathe naturally and normally during sleep—without relying on wearable devices or surgical implants. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to improve public health, enhance patients’ healthcare experiences, and create healthcare savings. The company’s headquarters are in London (UK).
About eXciteOSA®
eXciteOSA® is an innovative daytime therapy for sleep-disordered breathing. Clinically proven to target a common cause of OSA, eXciteOSA® uses neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles. This helps strengthen the intrinsic and extrinsic tongue muscles, improving endurance and preventing airway collapse during sleep. Unlike other devices used during sleep, eXciteOSA® is the first commercially available device designed for use while awake.
Signifier is committed to working with the sleep research community to produce high-quality evidence through rigorous clinical trials.
